Details for New Drug Application (NDA): 212613
✉ Email this page to a colleague
NDA 212613 describes GANIRELIX ACETATE, which is a drug marketed by Amphastar Pharms Inc, Gland Pharma Ltd, Lupin Ltd, Meitheal, and Organon Usa Organon, and is included in five NDAs. It is available from seven suppliers. Additional details are available on the GANIRELIX ACETATE profile page.
The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.
The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.
Summary for 212613
| Tradename: | GANIRELIX ACETATE |
| Applicant: | Amphastar Pharms Inc |
| Ingredient: | ganirelix acetate |
| Patents: | 0 |
Pharmacology for NDA: 212613
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Antagonists |
| Physiological Effect | Decreased GnRH Secretion |
Suppliers and Packaging for NDA: 212613
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GANIRELIX ACETATE | ganirelix acetate | INJECTABLE;INJECTION | 212613 | ANDA | Amphastar Pharmaceuticals, Inc. | 0548-5001 | 0548-5001-00 | 1 SYRINGE in 1 CARTON (0548-5001-00) / .5 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 250MCG/0.5ML | ||||
| Approval Date: | Apr 7, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
